Novel Percutaneous Treatment Strategies for Native Right Ventricular Outflow Tract Dysfunction-Clinical Outcomes of Self-Expanding Platforms

Clinical Outcomes of Self-Expanding Platforms – Review of the Data

Video Transcription

Video Summary

Matt Gillespie, the director of the Cath Lab at Children's Hospital of Philadelphia, discusses the clinical outcomes of two self-expanding platforms, Harmony and Altera. The Harmony trial, the first early feasibility trial for non-conductive, non-bioprosthetic pulmonary valve replacement, has shown good outcomes at two years, with no device-related mortality, minimal morbidity, and improved valve function. The Altera adaptive pre-stent trial has also demonstrated positive results, with good valve function, low incidence of adverse events, and improved quality of life for patients. However, real-world data and longer-term follow-up are needed to fully understand the impact of these technologies.

Asset Subtitle

Matthew J. Gillespie, MD, FSCAI

Keywords

Matt Gillespie

Cath Lab

Children's Hospital of Philadelphia

Harmony

Altera